Verastem is a biopharmaceutical company developing new medicines to improve the lives of patients with RAS/MAPK pathway-driven cancers.
Verastem Oncology has raised $250.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in October 2026.
Verastem Oncology's investors include Bessemer Venture Partners, Hercules Capital, RTW Investments, Nantahala Capital Management, OrbiMed.
Verastem Oncology is headquartered in Needham, United States.
Verastem is a biopharmaceutical company developing new medicines to improve the lives of patients with RAS/MAPK pathway-driven cancers.
Verastem Oncology is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Verastem Oncology — Funding & Investors." VCBacked, October 14, 2026, https://www.vcbacked.co/company/verastem-oncology. Accessed November 12, 2026.
VCBacked. (2026). Verastem Oncology — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/verastem-oncology
{{cite web |title=Verastem Oncology — Funding & Investors |url=https://www.vcbacked.co/company/verastem-oncology |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Verastem Oncology? Request a listing update